Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Non-pharmacologic interventions to improve outcomes in breast cancer care

Jennifer Ligibel • 16 Sep 2024
ESMO 2024
Breast Cancer

Jennifer Ligibel, MD, Dana Farber Cancer Institute, Boston, MA, comments on the role of non-pharmacologic interventions in managing side effects of breast cancer treatments, such as endocrine therapy and chemotherapy. Exercise can reduce fatigue, improve quality of life and cardiorespiratory fitness, as well as preventing lymphedema after surgery. Other therapies like acupuncture and yoga can also alleviate joint pain, fatigue, and sleep issues. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jennifer Ligibel

Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
Integration of weight management strategies into clinical practice for breast cancer patients
1:25
Integration of weight management strategies into clinical practice for breast cancer patients
Jennifer Ligibel • 31 May 2026
Weight loss intervention and QoL outcomes in breast cancer: BWEL trial
1:20
Weight loss intervention and QoL outcomes in breast cancer: BWEL trial
Jennifer Ligibel • 31 May 2026
Acupuncture for managing hot flashes in patients with breast cancer on endocrine therapy
1:01
Acupuncture for managing hot flashes in patients with breast cancer on endocrine therapy
Jennifer Ligibel • 16 Sep 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals